1、State of Digital HealthGlobal|Q3 2025Global data and analysis on dealmaking,funding,and exits by private market digital health companiesState of Digital Health2 2Action is better.We track and compare the worlds companies.Our AI agents keep you a step ahead of competitors and disruption.Trusted by th

2、e worlds smartest companies:Every big tech company.Every top professional services firm.26 of the top 30 banks.All ten Fortune 10 companies.Put our AI agents to work today.IIIIIIStart free trialState of Digital Health3 3“Steal”our data.Download the underlying data in this report.If you create any an

3、alysis or visualizations with this data,send it our way and you could be featured in the CBI newsletter.us on social LinkedIn X(Twitter)InstagramIIIIDownload the raw dataTL;DR 2025 CB Insights|4Your rundown ondigital health in Q32520%Mid-stage deals reach highest share in 5 years.Mid-stage deals rea

4、ched 20%in 2025 YTD,up from 18%in 2024 the highest in 5 years.Early-stage deals dropped to 57%from 63%in 2024.Annual median funding across all stages has increased in 2025 so far,with mid-stage deals rising to$23M(from$18.6M in 2024)and late-stage deals jumping to$47.5M(from$32M in 2024).This shift

5、reflects investors prioritizing more mature companies with proven traction.See the data 55M&A activity surges to highest level since Q123.See the data Four new unicorns(companies valued at$1B+)emerged in Q325 3 in the US and 1 in Asia doubling the amount from the previous quarter.All 4 of these unic

6、orns leverage AI in their core products,from life sciences platforms like Enveda(drug discovery)to provider tools like Ambience(clinical documentation)and UltraGreen(fluorescence-guided surgery).See the data 4New unicorns emerge despite market headwinds.$4.5BFunding and deals decline for 2nd consecu